STRATEGY...

We are strategic thinkers skilled in public policy analytics

VALUE...

We demonstrate to policymakers the value of your ideas

SOLUTIONS...

We collaborate to help you find solutions to public policy challenges

COMMUNICATION...

Years of experience let us talk numbers to any audience

STRATEGY...
We are strategic thinkers
skilled in public policy analytics
LEARN MORE >
VALUE...
We demonstrate to policymakers
the value of your ideas
LEARN MORE >
SOLUTIONS...
We collaborate to help you find
solutions to public policy challenges
LEARN MORE >
COMMUNICATIONS...
Years of experience
let us talk numbers to any audience
LEARN MORE >

WHO WE ARE

Matrix Global Advisors (MGA) is an economic policy consulting firm in Washington, DC, specializing in fiscal, health care, and tax policy matters. Drawing on years of policy experience, the MGA team writes white papers and expert reports, and offers strategic advice to our clients.

WHY US

Our Expertise. Founder and CEO Alex Brill served as the chief economist and policy advisor for the House Committee on Ways and Means from 2002 to 2007. Afterwards, he assembled the small, dedicated team of experts that comprise MGA.

Our Reputation. We are known for our unbiased analysis and strategic advice, as well as our strong ability to communicate to decision-makers. From Congressional testimony to economic studies to mass media, our insights are heard and appreciated.

Our Size. The small size of our firm is a distinguishing strength. Nothing is ever delegated—we directly handle all analysis, writing, and client interactions.

NEWS

Teva Economic Impact Report

This report, from Matrix Global Advisors (MGA), highlights Teva’s impact on economies in 15 of the 60 countries in which Teva operates. These 15 countries comprise 60 percent of Teva’s total global workforce and 75 percent of revenues in 2020. MGA’s detailed impact analysis estimates that, in 2020, Teva’s local purchases and payroll supported more than 249,000 jobs across these 15 countries, contributed $52 billion to economic output, and generated $11.7 billion in labor income.

Read more

MGA Report Featured by The Center for Biosimilars

On Thursday, The Center for Biosimilars, a sister site of The American Journal of Managed Care, published an article discussing the differences between the patent systems in the United States and Europe when it comes to biosimilars. The article featured the latest report released by MGA, and authored by Alex Brill and Christy Robinson, titled “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing”:

Read more

New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing

“How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” authored by Alex Brill and Christy Robinson, explains how reference biologic manufacturers create thickets of overlapping, weaker follow-on patents to keep competitors from entering the market. The paper highlights how originators have strong incentives to protect their profit streams and have found patent thickets to be an easy way to significantly extend the duration of monopolies in the US, preventing access to more affordable medicines for patients.

Read more
LEARN MORE ABOUT US